|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Immunopharmacology Research Group, Medical School, University of Tampere, Tampere, Finland (H.K., P.I., X.Z., E.M.); the Center for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China (X.Z.); Department of Respiratory Medicine (H.K.) and Research Unit (E.M.), Tampere University Hospital, Tampere, Finland; and OrionPharma Ltd., Espoo, Finland (E.N.)
Orazipone is a novel sulfhydryl-reactive compound that has been previously shown to reduce lung eosinophilia in guinea pigs and rats and to inhibit degranulation in mast cells and cytokine production in monocytes and T-cells. However, the effects of orazipone on granulocyte longevity are unknown. Orazipone and its derivative 3-(4-chloro-3-nitro-benzylidene)-pentane-2,4-dione (OR-2370) reversed interleukin-5-afforded survival of human eosinophils by inducing apoptosis. In contrast, orazipone did not affect granulocyte macrophage-colony-stimulating factor-induced survival of human neutrophils. The effect of orazipone on eosinophil apoptosis is different from that of glucocorticoids in that even high con-centrations of interleukin-5 were not able to overcome the effect of orazipone. Orazipone further enhanced spontaneous apoptosis as well as that induced by CD95 ligation without inducing primary necrosis. OR-2370-induced DNA fragmentation was shown to be dependent on caspases 3 and 6 and c-jun-N-terminal kinase, whereas extracellular regulated kinase, p38 mitogen-activated protein kinase, and phosphatidylinositol 3-kinase as well as caspases 4, 8, and 9 seem not to mediate its actions. Our results suggest that orazipone and its derivative OR-2370 possess strong antieosinophilic activity and thus may have anti-inflammatory efficacy in the treatment of asthma and/or allergic conditions.
Address correspondence to: Dr. Hannu Kankaanranta, The Immunopharmacology Research Group, Medical School/B, FIN-33014 University of Tampere, Finland. E-mail: blhaka{at}uta.fi
This article has been cited by other articles:
![]() |
O. Sareila, M. Hamalainen, E. Nissinen, H. Kankaanranta, and E. Moilanen Orazipone Inhibits Activation of Inflammatory Transcription Factors Nuclear Factor-{kappa}B and Signal Transducer and Activator of Transcription 1 and Decreases Inducible Nitric-Oxide Synthase Expression and Nitric Oxide Production in Response to Inflammatory Stimuli J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 858 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Kankaanranta, X. Zhang, R. Tumelius, M. Ruotsalainen, H. Haikala, E. Nissinen, and E. Moilanen Antieosinophilic Activity of Simendans J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 31 - 38. [Abstract] [Full Text] [PDF] |
||||